Anti-Human CD33 & CD3E Bispecific Reference Antibody (Eluvixtamab, RUO)

Description: Eluvixtamab (BS10703) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: (scFv-heavy-kappa)-(scFv-heavy-lambda)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: MyeloidcellsurfaceantigenCD33,Sialicacid-bindingIg-likelectin3,Siglec-3,CD33,gp67,SIGLEC3,T3E,T-cellsurfaceantigenT3/Leu-4epsilonchain,CD3e,CD3E,T-cellsurfaceglycoproteinCD3epsilonchain
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,AMG-330,MT-114,CAS:1679391-73-1
Background: Eluvixtamab is an anti-CD3E/CD33 monoclonal antibody.
Note: For research use only. Not suitable for clinical or therapeutic use.